Biogen Denies Misleading Investors Over Alzheimer's Drug

By Elliot Weld · July 28, 2022, 9:26 PM EDT

Healthcare giant Biogen denied making any misleading statements to its investors Wednesday in a motion to dismiss a securities class action alleging the company knew an Alzheimer's drug was deficient but...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login